Ipilimumab

Introduction Overview

Generic Name

ipilimumab

Brand Name

Yervoy

Dosage Form

intravenous infusion (50 mg/10 mL, 200 mg/40 mL)

Drug Class

Anti-CTLA-4 monoclonal antibodies

Pharmacokinetics

Absorption:
Ipilimumab, administered as an intravenous infusion, bypasses traditional absorption processes related to oral or other routes and is directly introduced into systemic circulation. The bioavailability following IV infusion is considered 100%, as the agent directly enters the bloodstream, allowing prompt distribution to target sites. The infusion is typically administered over 30 to 90 minutes to minimize infusion-related reactions and optimize patient tolerance.

Distribution:
Studies indicate that ipilimumab exhibits a steady volume of distribution indicative of limited tissue dissemination, consistent with monoclonal antibody pharmacology. As a large protein molecule, it primarily remains within the vascular and interstitial compartments, with limited penetration into the central nervous system due to the blood-brain barrier. Protein binding is typical of a monoclonal antibody, with distribution mainly influenced by binding to the CTLA-4 antigen expressed on T lymphocytes. The distribution kinetics can be affected by tumor burden and antigen presence, potentially influencing clearance rates.

Metabolism:
Ipilimumab undergoes catabolism via the reticuloendothelial system, similar to endogenous IgG antibodies. It is degraded to small peptides and amino acids through nonspecific proteolytic pathways. Unlike small molecule drugs, ipilimumab is not metabolized by cytochrome P450 enzymes, reducing concerns about hepatic metabolic drug interactions. The catabolic clearance correlates with IgG turnover rates and can be influenced by factors altering immune system activity or antibody-antigen binding dynamics.

Elimination:
Elimination of ipilimumab occurs mainly through proteolytic degradation following binding to its target, CTLA-4, or nonspecific endocytosis. The terminal half-life ranges approximately 15.4 days (with reported ranges from ~11 to 14.7 days in clinical studies), supporting dosing intervals of 3 to 6 weeks depending on indication and combination regimens. Clearance is reduced in patients with higher body weight or lower baseline tumor burden. There is no significant renal or biliary excretion of intact drug. The elimination phase may be prolonged in heavily pretreated patients or those with impaired immune clearance mechanisms, affecting dosing and monitoring strategies clinically.

Dosage Forms

Available Dosage Forms:
Yervoy is supplied as an intravenous infusion solution in single-dose vials at two concentrations: 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL). The formulation contains the active ingredient ipilimumab and inactive components such as diethylene triamine pentaacetic acid (DTPA), mannitol, polysorbate 80 (vegetable origin), sodium chloride, tris hydrochloride, and Water for Injection USP with a pH of 7.

Dosages for Adults and Adolescents:
Dosing is generally weight-based but often fixed at discrete dose levels tailored for specific indications. For melanoma and some other cancers, Yervoy is commonly dosed at 3 mg/kg IV infusion every 3 weeks for 4 doses, or as 10 mg/kg for adjuvant melanoma treatment. When combined with Opdivo (nivolumab), dosing regimens vary; for example, in melanoma, Yervoy 3 mg/kg IV is administered every 3 weeks for 4 doses, followed by maintenance nivolumab. In NSCLC, Yervoy may be given at 1 mg/kg every 6 weeks with nivolumab every 3 weeks for up to 2 years. Infusion duration ranges from 30 to 90 minutes.

Specific Patient Populations:
Yervoy is not approved for use in pediatric patients under 12 years old. Dosage adjustments in renal or hepatic impairment are not established, but caution is advised especially in patients with liver dysfunction or autoimmune disorders. The drug should be avoided or used carefully in patients with pre-existing autoimmune diseases or organ transplants because of the risk of severe immune-related adverse effects. In pregnant patients, the drug may cause fetal harm; effective contraception is recommended during treatment and for at least 3 months post-therapy. Breastfeeding is contraindicated during treatment and for at least 3 months following the last dose.

Mechanism Of Action

Ipilimumab is a fully human monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a critical immune checkpoint receptor present on T-cells. Under normal physiological conditions, CTLA-4 acts as a negative regulator of T-cell activation by outcompeting the stimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells, thereby maintaining immune homeostasis and preventing autoimmunity.

By binding to CTLA-4, ipilimumab blocks its interaction with B7 ligands, effectively releasing the brakes on T-cell activation. This blockade enhances T-cell proliferation, activation, and effector function, thereby augmenting immune responses against tumor cells. The reinvigoration of cytotoxic T lymphocytes facilitates immune-mediated tumor cell recognition and destruction.

Ipilimumab thereby functions as an immune checkpoint inhibitor, shifting the tumor microenvironment from an immunosuppressive milieu to one favoring antitumor immunity. It induces durable immune responses by promoting T-cell clonal expansion and memory formation against tumor-associated antigens.

Clinical studies have demonstrated that CTLA-4 inhibition with ipilimumab leads to improved survival outcomes in several malignancies such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. Compared to other immune checkpoint inhibitors targeting PD-1 or PD-L1, ipilimumab modulates T-cell priming and early activation steps in lymph nodes, offering a complementary immune boosting effect. The combination of ipilimumab with PD-1 inhibitors leverages these distinct mechanisms, resulting in synergistic antitumor efficacy and clinically improved response rates.

Pharmacological Actions

Immune checkpoint blockade via CTLA-4 receptor antagonism on T lymphocytes.
Enhancement of T-cell activation and proliferation leading to increased antitumor immune responses.
Augmentation of tumor-infiltrating lymphocyte activity and promotion of tumor cell lysis.
Induction of durable adaptive immune memory responses against tumor antigens.
Modulation of immune homeostasis potentially reactivating autoreactive T cells.
Synergistic action with PD-1 pathway inhibitors to enhance immune-mediated tumor eradication.
Inhibition of immune suppression within the tumor microenvironment.
Activation of cytotoxic CD8+ T cells critical for direct tumor cytotoxicity.

Therapeutic Or Clinical Uses

Treatment of unresectable or metastatic melanoma, including as adjuvant therapy post-surgery to delay recurrence.
Management of non-small cell lung cancer (NSCLC) expressing PD-L1 (≥1%) without EGFR or ALK genomic tumor aberrations, frequently in combination with nivolumab.
Treatment of unresectable malignant pleural mesothelioma in combination with nivolumab.
Therapy for advanced or metastatic renal cell carcinoma (kidney cancer), often with nivolumab co-administration.
Treatment of hepatocellular carcinoma (liver cancer) as part of combination immunotherapy regimens.
Management of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer.
Treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) with adjunctive nivolumab therapy.
Use in various cancers where immune checkpoint inhibition is indicated to stimulate antitumor immunity.
Off-label or investigational uses under clinical trials for other solid tumors expressing CTLA-4.
Combined immunotherapy protocols with other checkpoint inhibitors or chemotherapy depending on cancer type and stage.

Side Or Adverse Effects

Common side effects when used alone include nausea, fatigue, headache, diarrhea, weight loss, fever, itching, decreased appetite, rash, insomnia, and vomiting.
When combined with Opdivo (nivolumab), side effects also include stomach pain, shortness of breath, upper respiratory tract infection symptoms, muscle, bone, and joint pain, hypothyroidism, constipation, cough, dizziness.
Combination with chemotherapy increases the incidence of fatigue, rash, musculoskeletal pain, decreased appetite, nausea, constipation, diarrhea, and itching.
Serious adverse reactions include severe immune-mediated events affecting the gastrointestinal tract (severe diarrhea, colitis), liver (hepatitis), skin (severe rash, Stevens-Johnson syndrome), endocrine glands (hypophysitis, thyroid disorders), lungs (pneumonitis), kidneys (nephritis), and nervous system (neuropathy, encephalitis).
Infusion-related reactions manifesting as chills, fever, dizziness, shortness of breath, itching, and rash may occur during or shortly after administration.
Potentially fatal immune-related adverse effects requiring immediate medical attention such as chest pain, severe muscle weakness, neurologic symptoms, vision changes, and seizure.
Risk of hormonal disorders presenting as frequent headaches, dizziness, mood changes, altered thirst and urination patterns.
Delayed immune-related side effects can occur months after discontinuation of therapy.
Common laboratory abnormalities include elevated liver enzymes, low thyroid hormone levels, and hematologic changes.
Patients may experience infections due to immunomodulation or immunosuppression.
Rare but severe dermatologic reactions including blistering and peeling skin.
Potential exacerbation of pre-existing autoimmune conditions.

Precautions

Monitor patients closely for immune-related adverse events involving multiple organ systems.
Perform baseline and periodic assessments of liver function, thyroid function, renal function, and other relevant laboratory parameters.
Use caution in patients with pre-existing autoimmune diseases such as lupus, sarcoidosis, Crohn’s disease, or ulcerative colitis due to increased risk of exacerbations.
Inform patients about the risk of serious and potentially fatal immune-related side effects and the importance of early reporting symptoms.
Avoid use in patients with prior organ or stem cell transplantation due to potential for allograft rejection.
Pregnant patients should avoid use; effective contraception is essential during treatment and for at least 3 months afterward.
Breastfeeding is contraindicated during treatment and for at least 3 months post-therapy.
Patients must be monitored for infusion-related reactions during administration.
Dose modifications or treatment discontinuation may be necessary if severe adverse effects occur.
Careful patient selection is essential, especially in elderly patients or those with impaired organ function.
Advise patients to avoid infections and report signs of infection promptly.
Educate patients on symptom recognition of endocrinopathies, pneumonitis, colitis, and other immune-mediated toxicities.
Ensure vaccinations are up to date prior to therapy but avoid live vaccines during treatment.
Caution with concomitant immunosuppressive therapies which may blunt efficacy.
Patients should avoid administering unauthorized medications or supplements without consulting healthcare providers.

Warnings

Serious and sometimes fatal immune-mediated adverse reactions can occur during treatment or months after the last dose.
Monitor for signs of severe gastrointestinal toxicity including colitis and enterocolitis.
Risk of hepatotoxicity presenting as elevated liver enzymes, jaundice, and liver failure.
Potential for severe dermatologic reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis.
Warning for endocrinopathies including hypophysitis, adrenal insufficiency, and thyroid disorders potentially leading to life-threatening complications.
Pulmonary toxicity including pneumonitis with symptoms such as new or worsening cough, dyspnea, and chest pain.
Neurologic toxicity risk including Guillain-Barré syndrome, myasthenia gravis, and encephalitis.
Hypersensitivity and infusion-related reactions requiring immediate intervention.
Worsening of pre-existing autoimmune diseases and potential for graft rejection post-transplant.
Caution in pregnant or breastfeeding women due to potential fetal harm and drug excretion in human milk.
Discontinue therapy promptly if severe or life-threatening immune-related toxicities develop.
Frequent monitoring and patient education on symptom vigilance are critical for safe use.
Drug may impair ability to respond adequately to infections and vaccinations.
Risk of increased morbidity if immune toxicities are not promptly recognized and treated.
Patients should carry medical information identifying Yervoy therapy in case of emergency.

Contraindication

History of severe hypersensitivity or allergic reactions to ipilimumab or any of its inactive ingredients.
Active autoimmune disease requiring systemic immunosuppression due to risk of exacerbation.
Previous organ transplant recipients are generally contraindicated due to risk of rejection.
Known or suspected pregnancy unless potential benefits outweigh the risks due to fetal harm potential.
Severe liver impairment or active uncontrolled infections may contraindicate therapy.
Patients with neurologic disorders such as myasthenia gravis or Guillain-Barré syndrome that could worsen with immune activation.
Concomitant use with live vaccines during and after treatment until immune recovery.
Hypersensitivity to murine proteins or other monoclonal antibodies similar to ipilimumab.
Patients unable to comply with frequent monitoring and reporting requirements may be unsuitable for therapy.
Concurrent participation in conflicting clinical trials without medical oversight.

Drug Interactions

Potential for enhanced immunologic toxicity when combined with other immune checkpoint inhibitors such as nivolumab (Opdivo).
Concurrent use with systemic corticosteroids or immunosuppressants may decrease therapeutic efficacy but sometimes necessary to manage toxicity.
No significant cytochrome P450 metabolism, so minimal direct pharmacokinetic interactions with CYP substrates, inducers, or inhibitors.
Possible additive immunosuppressive effects with chemotherapy agents increasing infection risk.
Interactions with vaccines, especially live vaccines, posing risk of severe adverse reactions during immunotherapy.
Concomitant use of drugs causing hepatotoxicity may exacerbate liver toxicity risks.
Drugs affecting renal function can alter management of immune-related nephritis.
Medications causing QT prolongation require caution due to limited data on ipilimumab’s cardiac effects.
Potential interaction with biologic agents modulating the immune system where combined adverse effects may occur.
Medications that modify T-cell mediated immunity may alter the efficacy or toxicity profile of ipilimumab.
There is a lack of comprehensive data on interactions with herbal supplements or over-the-counter immunomodulators; caution is advised.
Drug interactions with other monoclonal antibodies used in oncology or autoimmune therapy need careful evaluation.
Potential alteration of immune checkpoint inhibitor activity in patients receiving antiviral or antibiotic agents with immunomodulatory properties.
Close monitoring recommended during polypharmacy in oncology regimens to detect unexpected adverse interactions.
Patients should inform providers of all concomitant medications, including nonprescription drugs and supplements.

Preparations Of The Drug

Yervoy is available as a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution.
Formulated as an intravenous infusion solution containing ipilimumab at 5 mg/mL concentration.
Single-dose vials of 50 mg/10 mL and 200 mg/40 mL are supplied for dilution prior to administration.
Inactive ingredients include diethylene triamine pentaacetic acid (DTPA), mannitol, polysorbate 80 (vegetable origin), sodium chloride, tris hydrochloride, and Water for Injection USP with adjusted pH 7.
The drug must be stored refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton, protected from light.
Do not freeze or shake the vial to prevent protein denaturation and loss of efficacy.
Prior to infusion, Yervoy is diluted according to prescribing guidelines in appropriate volume of sterile 0.9% sodium chloride solution.
The prepared infusion solution should be used promptly and not stored for extended periods after dilution.
Administered via intravenous infusion over 30 to 90 minutes under healthcare supervision in medical settings.
Handling requires aseptic technique and precautions to avoid exposure and contamination.
No preservatives are included; thus, single-use vials must be discarded after initial use.
Manufactured by Bristol-Myers Squibb Company with stringent quality control to ensure potency and safety.
Biosimilar products for ipilimumab exist but must meet FDA standards for similarity and interchangeability with Yervoy.
Packaging and labeling include detailed instructions for storage, preparation, administration, and safety warnings.
Proper disposal of unused drug and materials should comply with biomedical waste regulations.